{"abstract": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work.", "web_url": "https://www.nytimes.com/2016/11/25/business/dealbook/johnson-johnson-actelion.html", "snippet": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work.", "lead_paragraph": "Actelion could give Johnson & Johnson hypertension.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Johnson & Johnson Has Its Eye on Actelion", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Actelion Pharmaceuticals Ltd", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 4, "major": "N"}], "pub_date": "2016-11-25T21:22:24+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Neil Unmack", "person": [{"firstname": "Neil", "middlename": null, "lastname": "Unmack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c810e88c-6679-5592-917d-a0253ae74e7e", "word_count": 425, "uri": "nyt://article/c810e88c-6679-5592-917d-a0253ae74e7e"}